

**ASX ANNOUNCEMENT
27 MARCH 2023**

Radiopharm Theranostics, GenesisCare, Partner to Develop Novel Radiopharmaceuticals in Australia

- *Multi-year strategic research partnership will see Radiopharm Theranostics collaborate with GenesisCare's Contract Research Organisation and Imaging Research Organisation to develop new therapies on Australian soil.*
- *Research partnership brings together two Australian healthcare organisations to develop novel radiopharmaceutical treatments for some complex, hard-to-treat cancers.*
- *Australia's regulatory landscape facilitates R&D for theranostics and precision medicine.*

Sydney, Australia – Radiopharm Theranostics, a clinical-stage radiotherapeutics company, and GenesisCare, a leading global provider of integrated cancer care and theranostics research, have today announced a new two-year strategic research collaboration to develop novel radiopharmaceuticals for some complex, hard-to-treat cancers. Through the partnership, Radiopharm Theranostics and GenesisCare will conduct Phase 1 clinical trials in Australia to study the safety and tolerability of novel radiopharmaceuticals, focusing on areas of high unmet need in oncology.

As part of the collaboration, GenesisCare's Contract Research Organisation (CRO) and Imaging Research Organisation (IRO), have been engaged to implement three Phase 1 clinical trials in Australia, involving Radiopharm's platform of radiopharmaceutical nanobodies.^{1,2}

Radiopharmaceuticals are designed to deliver small doses of radiation to specifically targeted cells for either therapeutic or diagnostic purposes. Effective cancer radiopharmaceuticals require tumour-specific targets not found in healthy tissue.³ To date, the majority of clinical developments in radiopharmaceuticals have targeted metastatic prostate cancer and neuroendocrine tumours.⁴

The three Phase 1 clinical trials to be conducted by GenesisCare for Radiopharm under the research partnership are :

1. Phase 1 trial involving Radiopharm's proprietary nanobody from its Nano-mAbs platform which targets the PDL1 expression in non-small cell lung cancer
2. Phase 1 trial involving Radiopharm's PTPu targeting peptide in Brain Tumors
3. Phase 1 trial involving Radiopharm's PSA targeting antibody which targets free human prostate kallikrein (PSA) in prostate cancer cells.

Radiopharm's Chief Executive Officer & Managing Director, Riccardo Canevari, said:

"Radiopharmaceuticals are quickly becoming a highly promising therapeutic frontier in oncology, offering new hope to patients who may have exhausted all other treatment options.

"We are delighted to be extending and strengthening our partnership with GenesisCare, a world-leader in cancer care, to advance the future of radiopharmaceuticals and improve access to innovative therapies for patients all over the world."

GenesisCare's Chief Scientific Officer, Research & Insights, Dr Danielle Meyrick, PhD, said: "We are delighted to be partnering with Radiopharm on its exciting pipeline of research in Australia. This R&D collaboration brings together two Australian-founded healthcare companies who share an interest in investigating and developing new therapies in Australia."

Media contact information:

Radiopharm:

Matt Wright NWR Communications

M: +61 451 896 420 E: matt@nwrcommunications.com.au

Background:

About Radiopharm

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of six distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world's leading universities and institutes. The pipeline has been built based on the potential to be first to market or best in class. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumour cancers including breast, kidney and brain. Learn more at RadiopharmTheranostics.com.

References:

1. Radiopharm, 23rd March 2022, *Radiopharm Theranostics teams up with GenesisCare*, [Press Release], <<https://themarketherald.com.au/radiopharm-theranostics-asxrad-teams-up-with-genescare-2022-03-23/>>
2. Radiopharm, 1st July 2022, *Theranostics extends agreement for Australian prostate cancer trial with GenesisCare*, [Press Release], <<https://www.proactiveinvestors.com.au/companies/news/986376/radiopharm-theranostics-extends-agreement-for-australian-prostate-cancer-trial-with-genescare-986376.html>>
3. Duan H, Iagaru A, Aparici CM. Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging. *Nanotheranostics*. 2022 Jan 1;6(1):103-117. doi: 10.7150/ntno.64141. PMID: 34976584; PMCID: PMC8671964.
4. Theranostics: A Smart Bomb For Cancer, Memorial Sloan Kettering Cancer Center MSK News Winter 2021/2022, accessed November 2022, <https://www.mskcc.org/msk-news/winter-2021-22/theranostics-smart-bomb#:~:text=Today%2C%20the%20cancers%20most%20commonly,good%20targets%20on%20cancer%20cells.>